Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: The present invention comprises a method for the generation of 227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said 223Ra and 227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting 227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first 227Th solution containing contaminant 223Ra and 227Ac; v) loading the first 227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant 223Ra and 227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the 227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second 227Th solution.

Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: The present invention comprises a method for the generation of 227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said 223Ra and 227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting 227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first 227Th solution containing contaminant 223Ra and 227Ac; v) loading the first 227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant 223Ra and 227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the 227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second 227Th solution.

Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: The present invention provides a method for the purification of 227Th from a mixture comprising 227Th and 223Ra, said method comprising: i) preparing a first solution comprising a mixture of 227Th and 223Ra ions dissolved in an aqueous solution of first mineral acid; ii) loading said first solution onto a strong base anion exchange resin; iii) eluting 223Ra from said strong base anion exchange resin using a second mineral acid in an aqueous solution; iv) optionally rinsing said strong base anion exchange resin using a first aqueous medium; v) eluting 227Th from said strong base anion exchange resin using a third mineral acid in an aqueous solution whereby to generate a second solution comprising 227Th. The invention further provides a purified 227Th solution, a corresponding pharmaceutical formulation and methods of treatment of neoplastic disease.

Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: The present invention provides a method for the purification of 227Th from a mixture comprising 227Th and 223Ra, said method comprising: i) preparing a first solution comprising a mixture of 227Th and 223Ra ions dissolved in an aqueous solution of first mineral acid; ii) loading said first solution onto a strong base anion exchange resin; iii) eluting 223Ra from said strong base anion exchange resin using a second mineral acid in an aqueous solution; iv) optionally rinsing said strong base anion exchange resin using a first aqueous medium; v) eluting 227Th from said strong base anion exchange resin using a third mineral acid in an aqueous solution whereby to generate a second solution comprising 227Th. The invention further provides a purified 227Th solution, a corresponding pharmaceutical formulation and methods of treatment of neoplastic disease.

Abstract: The present invention comprises a method for the generation of 227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said 223Ra and 227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting 227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first 227Th solution containing contaminant 223Ra and 227Ac; v) loading the first 227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant 223Ra and 227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the 227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second 227Th solution.

Abstract: The present invention relates to improved radiotracer imaging agent compositions, which comprises 18F-labelled biological targeting moieties, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are radiopharmaceuticals comprising said improved compositions, together with radiofluorinated aldehyde compositions useful in preparing said radiotracer compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.

Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: A method for the purification of cyclic indole compounds that provides advantages over previously-known methods. Using the method of the present invention allows for the facile preparation of a good quality solid form of these compounds.

Abstract: A method for the purification of cyclic indole compounds that provides advantages over previously-known methods. Using the method of the present invention allows for the facile preparation of a good quality solid form of these compounds.

Abstract: A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Flutemetamol (18F) Injection for the imaging of ?-amyloid plaques in the brain and methods and devices for preparing same are described including the automated synthesis and purification of [18F]flutemetamol by means of solid phase extraction (SPE).

Abstract: The present invention relates to improved radiotracer imaging agent compositions, which comprises 18F-labelled biological targeting moieties, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are radiopharmaceuticals comprising said improved compositions, together with radiofluorinated aldehyde compositions useful in preparing said radiotracer compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.

Abstract: The present invention relates to improved radiotracer imaging agent compositions, which comprises 18F-labelled biological targeting moieties, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are radiopharmaceuticals comprising said improved compositions, together with radiofluorinated aldehyde compositions useful in preparing said radiotracer compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.

Abstract: A diagnostic imaging agent useful for positron emission tomography (PET) imaging as well as to improved hardware for producing such imaging agents is described. Flutemetamol (18F) Injection for the imaging of ?-amyloid plaques in the brain and methods and devices for preparing same are described including the automated synthesis and purification of [18F]flutemetamol by means of solid phase extraction (SPE).

Abstract: The present invention provides a method to prepare an 18F-labelled tricyclic indole compound comprising a solid-phase extraction (SPE) purification step. This method is particularly suitable for carrying out the radiofluorination method on an automated synthesizer. In addition to the radiofluorination method, the present invention provides a cassette designed to carry out the method on an automated synthesizer.

Abstract: The present invention relates to a method of purification of [18F]-fluciclatide via solid phase extraction (SPE). The method is amenable to automation, and is suitable for use in conjunction with automated synthesizer apparatus—especially cassette-based synthesizers. Also provided are cassettes for carrying out the purification method.